• 27 September 2018

Bioiberica to present a new Atopivet Spot-On study at the European Veterinary Dermatology Congress

  • The 30th Congress, co-hosted by the ESVD-ECVD, it is being held in Dubrovnik on 27-29 September 2018
  • New data of an in vitro study confirming the benefits of sfingolipids and glicosaminogliccans in dermatitis
See all news
Bioiberica to present a new Atopivet Spot-On study at the European Veterinary Dermatology Congress

Bioiberica will be present at the European Veterinary Dermatology Congress, held in Dubrovnik, Croatia, on 27-29 September 2018, to show the most recent dermatology findings of their R&D Department. More precisely, they will present a conference and a poster: “Effects of sphingolipids, glycosaminoglycans, and their combination on in vitro filaggrin expression using reconstructed human epidermis”. 

A combination of sphingolipids and glycosaminoglycans significantly improved filaggrin expression in an in vitro study using a model of reconstructed human epidermis simulating skin inflammation. Filaggrin is a protein which plays an important role in the creation of the epidermal barrier. Therefore, this combination of active ingredients could become a useful complimentary treatment for atopic dermatitis.

Atopic dermatitis is a condition highly prevalent in cats and dogs, affecting some 10 percent of animals. The addition of Atopivet Spot-On as a complimentary tool for the management of dermatitis could be highly useful, not only to improve symptoms, but also (as proved by the most recent studies) to rebuild the skin’s protective barrier.

Atopivet Spot-On is a hygiene product for cats and dogs. It is available in pipettes-the product is applied directly to the dermatitis-affected skin. Its formulation, based on sphingolipids, glycosaminoglycans and hyaluronic acid, favors the restoration of the skin barrier function, which in turn helps reducing the inflammation and rash associated to atopic dermatitis.  

Other news from Pets

View all news from Pets